HIGHLIGHTS
- who: L. Hoffmann from the Deptof Oncology, Aarhus University Hospital, Denmark have published the research: Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours, in the Journal: (JOURNAL)
- what: The authors report on the protocol design and QA process, that aimed at ensuring consistency in OAR delineation and treatment planning. The authors bring this a step further and report on the dosimetric consequences of OAR delineation variations in treatments . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.